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The sodium-glucose cotransporter (SGLT) 2 offer a novel approach to treating type 2 diabetes by reducing
hyperglycaemia via increased urinary glucose excretion. In the present study, the pharmacokinetic,
pharmacodynamic, and pharmacologic properties of all six SGLT2 inhibitors commercially available in
Japan were investigated and compared. Based on ﬁndings in normal and diabetic mice, the six drugs
were classiﬁed into two categories, long-acting: ipragliﬂozin and dapagliﬂozin, and intermediate-acting:
tofogliﬂozin, canagliﬂozin, empagliﬂozin, and luseogliﬂozin. Long-acting SGLT2 inhibitors exerted an
antihyperglycemic effect with lower variability of blood glucose level via a long-lasting increase in
urinary glucose excretion. In addition, ipragliﬂozin and luseogliﬂozin exhibited superiority over the
others with respect to fast onset of pharmacological effect. Duration and onset of the pharmacologic
effects seemed to be closely correlated with the pharmacokinetic properties of each SGLT2 inhibitor,
particularly with respect to high distribution and long retention in the target organ, the kidney. While all
six SGLT2 inhibitors were signiﬁcantly effective in increasing urinary glucose excretion and reducing
hyperglycemia, our ﬁndings suggest that variation in the quality of daily blood glucose control associated
with duration and onset of pharmacologic effects of each SGLT2 inhibitor might cause slight differences
in rates of improvement in type 2 diabetes.
© 2016 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Due to increasing prevalence of obesity and physical inactivity,
the number of patients with diabetes is dramatically increasing and
is expected to rise to 366 million worldwide by 2030 (1). Approx-
imately 90% of all patients with diabetes have type 2 diabetes, a
progressive metabolic disease characterized by hyperglycemia and
relative insulin deﬁciency as a result of impaired insulin secretion
from pancreatic b-cells or insulin resistance. Chronic hyperglyce-
mia leads to progressive impairment of insulin secretion, exacer-
bates insulin resistance, and worsens diabetes (2). However, while
many antidiabetic drugs have been developed and used for treat-
ment, most type 2 diabetic patients' therapeutic goals are still noth, Astellas Pharma Inc., 21
81 29 847 8911; fax: þ81 29
ahara).
rmacological Society.
. Production and hosting by Elseachieved (3), highlighting the need for efﬁcient new therapeutic
strategies for treating type 2 diabetes, including combination
therapy.
In recent years, inhibitors of sodium-glucose cotransporter
(SGLT) 2, which can inhibit reabsorption of glucose by blocking
SGLT2 and stimulate glucose excretion in the urine, have been
proposed as novel drugs for treating type 2 diabetes (4), with
several shown to improve hyperglycemia in this patient population
(5). Although many studies have focused on nonclinical and clinical
pharmacologic effects of SGLT2 inhibitors (6,7), most have exam-
ined these compounds on an individual basis, with only one study
comparing several SGLT2 inhibitors in terms of in vitro inhibitory
activity and selectivity for SGLT2 (8) and none comparing their
in vivo effects.
Here, to clarify and compare the pharmacological properties of
all six SGLT2 inhibitors commercially available in Japan (ipragli-
ﬂozin, dapagliﬂozin, tofogliﬂozin, canagliﬂozin, empagliﬂozin, and
luseogliﬂozin), we conducted pharmacokinetic, pharmacodynamic,
and pharmacologic experiments in normal and type 2 diabetic
mice.vier B.V. This is an open access article under the CC BY-NC-ND license (http://
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2.1. Materials
Ipragliﬂozin (9), dapagliﬂozin (10), tofogliﬂozin (11), canagli-
ﬂozin (12), empagliﬂozin (8), and luseogliﬂozin (13) were synthe-
sized at Astellas Pharma Inc. (Ibaraki, Japan) and suspended in 0.5%
methylcellulose solution for oral administration. Drugs were
administered around the beginning (19:00) of the active period of
mice, which corresponds to the administration timing in clinical
practice. Doses of drugs were expressed as the free base form.
2.2. Animals
Male ICR (normal) mice for investigating pharmacokinetic and
pharmacodynamic properties were purchased from Japan SLC, Inc.
(Shizuoka, Japan). Male C57BL/6 (normal) and KK/Ay type 2 diabetic
mice for investigating pharmacologic effects were purchased from
CLEA Japan (Kanagawa, Japan). The diabetic mice were uniformly
grouped by blood glucose levels. All animals were housed under
conventional conditions with controlled temperature, humidity,
and light (12-h lightedark cycle) and were provided with standard
commercial diet and water ad libitum. All animal experimental
procedures were approved by the Institutional Animal Care and Use
Committee of Astellas Pharma Inc. Astellas Pharma Inc., Tsukuba
Research Center was awarded Accreditation Status by the AAALAC
International.
2.3. Pharmacokinetics
After oral administration of each SGLT2 inhibitor (3 mg/kg) to
nonfasting normal mice in the evening (19:00), blood was with-
drawn from the abdominal vena cava, and tissues (kidney, liver, and
brain) were isolated under isoﬂurane anesthesia at designated time
points for up to 24 h. Isolated tissues were homogenized with
phosphate-buffered saline. The plasma and tissue concentrations of
the test drug were measured using high-performance liquid chro-
matography (HPLC). Acetonitrile (100 mL) and methyl tert-butyl
ether (100 mL) were added to the plasma or tissue homogenate
(100 mL), mixed, and centrifuged (15,000 rpm, 10 min). The super-
natant was transferred to a tube and evaporated in a vacuum
centrifugal concentrator, and the residue was dissolved in the
mobile phase for use as the assay sample. Concentrations of drug in
assay sample were analyzed using HPLC with an ultraviolet de-
tector (ipragliﬂozin and tofogliﬂozin: 265 nm, dapagliﬂozin, cana-
gliﬂozin, empagliﬂozin, and luseogliﬂozin: 280 nm) and a
4.6  250-mm reversed-phase ODS-80Ts column (Tosoh, Tokyo,
Japan). The column temperature was maintained at 60 C, the
mobile phase used was acetonitrile/20 mM ammonium acetate
solution (60/40 [v/v]), and the ﬂow rate was 1 mL/min. The phar-
macokinetic parameters, maximum plasma/tissue concentration
(Cmax), time to Cmax (Tmax), elimination half-life (t1/2), and area
under the plasma/tissue drug concentrationetime curve (AUC) for
24 h, were calculated.
2.4. Pharmacodynamics
Each SGLT2 inhibitor (ipragliﬂozin and dapagliﬂozin: 0.3e3 mg/
kg, tofogliﬂozin, canagliﬂozin, empagliﬂozin, and luseogliﬂozin:
1e10 mg/kg) was administered orally in the evening (19:00) to the
normal mice under nonfasting conditions. Spontaneously voided
urine was collected every 6 h throughout the ﬁrst 24 h after dosing
while the animals were kept in metabolic cages under nonfasting
conditions. After the urine volume was measured, the glucoseconcentration in the urine was measured using the Glucose CII test
reagent (Wako Pure Chemical Industries, Ltd., Osaka, Japan).
2.5. Effects of SGLT2 inhibitors on blood glucose and plasma insulin
levels
Each SGLT2 inhibitor (ipragliﬂozin and dapagliﬂozin:
0.01e3 mg/kg, tofogliﬂozin, canagliﬂozin, empagliﬂozin, and
luseogliﬂozin: 0.03e10 mg/kg) was administered orally in the
evening (19:00) to diabetic mice, and blood samples were ob-
tained from a tail vein at each sampling point for up to 24 h under
nonfasting conditions. Blood sampling during nighttime (dark
period) was performed using a spotlight to minimize lighting,
taking special care not to affect food consumption or related pa-
rameters. Blood glucose concentrations were measured as
described above. Plasma insulin levels were measured using an
ultra-high sensitive mouse insulin enzyme-linked immunosor-
bent assay (ELISA) kit (Morinaga Institute of Biological Science,
Inc., Kanagawa, Japan).
2.6. Effects of SGLT2 inhibitors on glucose tolerance during the oral
glucose tolerance tests
Durability experiment: Each SGLT2 inhibitor (3 mg/kg) was
administered orally in the evening (19:00) to diabetic mice fasted
for half a day, and glucose solution (2 g/kg) was orally loaded 0.5, 6,
and 12 h after drug administration. Blood samples were obtained at
each sampling point.
Rapid-onset experiment: Each SGLT2 inhibitor (3 mg/kg) was
administered orally in the evening (19:00) to diabetic mice fasted
for half a day at 30 min before, 5 min before, or 10 min after oral
loading of glucose solution (2 g/kg). Blood samples were obtained
at each sampling point.
2.7. Statistical analysis
The experimental results are expressed as the mean,
mean± standard deviation (SD), ormean ± standard error of means
(SEM). The AUCs were calculated from blood glucose and plasma
insulin concentrations measured over time. Signiﬁcance of differ-
ences between normal and diabetic vehicle groups was assessed
using Student's t-test, while that between the vehicle- and drug-
treated groups was assessed using Dunnett's multiple comparison
test. A value of P < 0.05 was considered to be signiﬁcant. Statistical
and data analyses were conducted using GraphPad Prism 5
(GraphPad Software, La Jolla, CA, USA).
3. Results
3.1. Pharmacokinetics
Following oral administration of each SGLT2 inhibitor (3 mg/kg)
to normal mice, the maximum plasma concentration was reached
at 0.5e1 h, followed by time-dependent elimination (Fig. 1 and
Table 1). The drug concentrations in the kidney, liver, and brain
also peaked at 0.5e1 h, followed by time-dependent elimination.
Although distribution in the brain was low for all SGLT2 inhibitors,
distribution in the kidney, the SGLT2-expressing site, varied widely
among drugs. Tmax, as determined from drug concentrations in
plasma and kidney, was 0.5 h for ipragliﬂozin and luseogliﬂozin
and 1 h for the other four drugs. The t1/2 was longest in plasma in
the descending order of canagliﬂozin > dapagliﬂozin > ipragli-
ﬂozin > empagliﬂozin > tofogliﬂozin > luseogliﬂozin and longest
in kidney in the descending order of dapagliﬂozin > ipragliﬂozin >
canagliﬂozin > empagliﬂozin ¼ tofogliﬂozin > luseogliﬂozin.
(a) Ipragliflozin (b) Dapagliflozin (c) Tofogliflozin
(d) Canagliflozin (e) Empagliflozin (f) Luseogliflozin
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Fig. 1. Pharmacokinetics of SGLT2 inhibitors in normal mice. Time course of changes in plasma, renal, hepatic, and brain concentrations of drug, and plasma or tissue area under the
drug concentrationetime curve (AUC) for 24 h. Each SGLT2 inhibitor (3 mg/kg) was orally administered to normal mice. Each data point expresses mean or mean ± SD for three
animals.
A. Tahara et al. / Journal of Pharmacological Sciences 130 (2016) 159e169 161The kidney/plasma AUC ratio (distribution in the kidney) was
highest in the descending order of ipragliﬂozin > dapagliﬂozin ¼
canagliﬂozin > empagliﬂozin > luseogliﬂozin > tofogliﬂozin.3.2. Pharmacodynamics
Following administration of each SGLT2 inhibitor (3 mg/kg) to
normal mice, signiﬁcantly increased urinary glucose excretion was
noted in a dose-dependent manner (Fig. 2). These effects of tofo-
gliﬂozin, canagliﬂozin, empagliﬂozin, and luseogliﬂozin were
markedly attenuated from 12 h post-dose, resulting in non-
signiﬁcant effects from 18 h post-dose. In contrast, the effects of
ipragliﬂozin and dapagliﬂozin were longer-lasting than other
SGLT2 inhibitors, with a signiﬁcant increase in urinary glucose
excretion noted even after 18 h post-dose. In addition, all drugs
induced a slight increase in urine volume (data not shown).3.3. Effects of SGLT2 inhibitors on blood glucose and plasma insulin
levels
Following administration of each SGLT2 inhibitor (0.01e10 mg/
kg) to diabetic mice, blood glucose and plasma insulin levels were
signiﬁcantly reduced in a dose-dependent manner (Fig. 3 and
Fig. 4). The effects were comparable for all drugs until 8 h after
dosing, although the effective doses varied, but were stronger with
ipragliﬂozin and dapagliﬂozin than with the other four drugs until
24 h after dosing (Fig. 5). When compared at doses that produced
comparable reductions in 24-h blood glucose and plasma insulin
levels (ipragliﬂozin and dapagliﬂozin, 0.3 mg/kg; tofogliﬂozin,
canagliﬂozin, empagliﬂozin, and luseogliﬂozin, 10 mg/kg), standard
deviations of blood glucose and plasma insulin levels for 24 h were
smaller with ipragliﬂozin and dapagliﬂozin than with the other
four drugs (Fig. 6).
Table 1
Pharmacokinetics of SGLT2 inhibitors in normal mice.
Cmax (ng/mL) (ng/g tissue) Tmax (h) t1/2 (h) AUC0e24 h (ng,h/mL) (ng,h/g tissue) Tissue/plasma AUC ratio
Ipragliﬂozin Plasma 1230 0.5 2.1 4520 1
Kidney 18,871 0.5 4.1 126,000 28
Liver 8074 0.5 1.2 19,300 4
Brain 959 0.5 1.1 2090 0.5
Dapagliﬂozin Plasma 1130 1 2.4 2970 1
Kidney 5448 1 4.2 29,200 10
Liver 4719 1 1.5 8750 3
Brain 464 1 1.3 904 0.3
Tofogliﬂozin Plasma 439 1 1.3 1010 1
Kidney 1202 1 2.1 3170 3
Liver 3597 1 1.5 7930 8
Brain 157 1 1.6 315 0.3
Canagliﬂozin Plasma 449 1 3.1 1620 1
Kidney 4103 1 3.2 16,600 10
Liver 3593 1 2.4 11,800 7
Brain 214 1 1.9 532 0.3
Empagliﬂozin Plasma 253 1 1.8 626 1
Kidney 1570 1 2.1 4200 7
Liver 1056 1 2.2 2930 5
Brain 171 1 1.5 313 0.5
Luseogliﬂozin Plasma 394 0.5 0.4 478 1
Kidney 978 0.5 1.4 2690 6
Liver 5288 0.5 0.6 7990 17
Brain 188 0.5 0.3 157 0.3
Each mouse was treated with a single oral dose (3 mg/kg) of drug. Pharmacokinetic parameters are expressed as the mean for three animals at each time point.
A. Tahara et al. / Journal of Pharmacological Sciences 130 (2016) 159e1691623.4. Effects of SGLT2 inhibitors on glucose tolerance during the oral
glucose tolerance test
The oral glucose tolerance test (OGTT) performed at 0.5 h after
administration of each SGLT2 inhibitor (3 mg/kg) showed signiﬁ-
cant improvement in glucose tolerance with all drugs, which
exerted comparable effects (Fig. 7A). The OGTT at 6 h after dosing
also showed signiﬁcant improvement in glucose tolerance with all
drugs, although the effect strengthened with ipragliﬂozin and
dapagliﬂozin and weakened with the other four drugs (Fig. 7B). At
12 h after dosing, glucose tolerance was signiﬁcantly improved
with ipragliﬂozin and dapagliﬂozin but not with the other four
drugs (Fig. 7C).
Following administration of each SGLT2 inhibitor (3 mg/kg) at
30 min before oral glucose loading, signiﬁcant improvements in
glucose tolerance and reductions in plasma insulin level were noted
with all SGLT2 inhibitors, which exerted comparable effects (Fig. 8
left). In contrast, following administration immediately before
(5 min before) or after (10 min after) oral glucose loading, glucose
tolerance was signiﬁcantly improved with all drugs; however, the
effect was stronger with ipragliﬂozin and luseogliﬂozin than with
the other four drugs, and the associated reduction in plasma insulin
level was signiﬁcant only for ipragliﬂozin and luseogliﬂozin (Fig. 8
center and right).
4. Discussion
Given substantial recent evidence supporting their usefulness
for reducing hyperglycemia in clinical settings, various SGLT2 in-
hibitors have been used as antidiabetic drugs. All of these drugs
have selective inhibitory activity for SGLT2, with many studies
reporting their effects in reducing hyperglycemia through increases
in urinary glucose excretion, both in nonclinical animal models and
in type 2 diabetic patients. Most of these studies, however, have
focused on the pharmacologic effects of individual SGLT2 in-
hibitors, with no studies performed to compare pharmacologic
properties across multiple SGLT2 inhibitors. The present study
involved pharmacokinetic, pharmacodynamic, and pharmacologicexperiments to compare the characteristics of all six SGLT2 in-
hibitors commercially available in Japan: ipragliﬂozin, dapagli-
ﬂozin, tofogliﬂozin, canagliﬂozin, empagliﬂozin, and luseogliﬂozin.
Pharmacokinetic experiments showed ipragliﬂozin and luseo-
gliﬂozin to have the shortest Tmax at 0.5 h, as determined from drug
concentrations in plasma and the SGLT2-expressing tissue kidney.
The t1/2 was longest in plasma with canagliﬂozin, followed by
dapagliﬂozin, ipragliﬂozin, empagliﬂozin, tofogliﬂozin, and luseo-
gliﬂozin, and longest in kidney with dapagliﬂozin, followed by
ipragliﬂozin, canagliﬂozin, empagliﬂozin and tofogliﬂozin (roughly
the same), and luseogliﬂozin, showing different persistence of
canagliﬂozin concentration between plasma and kidney. The kid-
ney/plasma AUC ratio (distribution in the kidney) was highest with
ipragliﬂozin, followed by dapagliﬂozin and canagliﬂozin (roughly
the same), empagliﬂozin, luseogliﬂozin, and tofogliﬂozin, showing
correlation with the persistence of drug concentration in the kid-
ney. The large difference among the drugs in distribution in the
kidney suggests that this characteristic might depends on a com-
pound's chemical structure.
The pharmacodynamic experiments revealed that all SGLT2
inhibitors increased urinary glucose excretion dose-dependently
and signiﬁcantly, although the duration of action differed among
the drugs. Ipragliﬂozin and dapagliﬂozin exhibited persistent ac-
tion, with signiﬁcant increase in urinary glucose excretion noted
even after 18 h post-dose, whereas the effects of tofogliﬂozin,
canagliﬂozin, empagliﬂozin, and luseogliﬂozin were markedly
attenuated from 12 h post-dose, resulting in non-signiﬁcant effects
from 18 h post-dose. Consistent with their long duration of action,
ipragliﬂozin and dapagliﬂozin showed long t1/2 in plasma. How-
ever, despite the long t1/2 of its plasma concentration, the phar-
macologic effect of canagliﬂozin was not persistent, in contrast to
ipragliﬂozin and dapagliﬂozin.
The results suggested close correlation of duration of action of
SGLT2 inhibitors with not only plasma drug concentration but also
drug distribution and retention in the kidney. A similar report
published previously noted discrepancies between the time course
of plasma drug concentration and persistence of increase in urinary
glucose excretion, proposing a close relationship between
Fig. 2. Effect of SGLT2 inhibitors on urinary glucose excretion in normal mice. Each SGLT2 inhibitor was orally administered to mice, and spontaneously voided urine was collected
every 6 h: (a) 0e6 h, (b) 6e12 h, (c) 12e18 h, and (d) 18e24 h, for 24 h. The values are the mean ± SEM for ﬁve animals in each group. *P < 0.05 vs. vehicle group.
A. Tahara et al. / Journal of Pharmacological Sciences 130 (2016) 159e169 163durability of pharmacologic effect and local drug concentration in
the renal proximal tubule, the SGLT2-expressing site (14). While
SGLT2 inhibitors are converted to various metabolites through the
metabolic process in the body, only tofogliﬂozin and luseogliﬂozin
produce pharmacologically active metabolites, and the proportion
of these active metabolites is only a small fraction of the concen-
trations of their respective parent drugs, showing that none of the
active metabolites contribute to the durability of pharmacologic
effect (15e20). Further, the results of in vitro binding experiments
have suggested that the difference in the rate of dissociation of a
drug from SGLT2 may be associated with duration of action (21).
The present study was limited to investigation of drug concentra-
tion in the whole kidney and did not examine renal local drugconcentrations or rate of drug dissociation from SGLT2. As such,
further investigation is warranted.
The 24-h blood glucose and plasma insulin measurements
revealed dose-dependent, signiﬁcant reductions in blood glucose
and plasma insulin levels with all drugs. The effects were compa-
rable for all drugs until 8 h after dosing but were stronger with
ipragliﬂozin and dapagliﬂozin than with the other four drugs on
observation until 24 h after dosing. The OGTT also produced similar
results: ipragliﬂozin and dapagliﬂozin signiﬁcantly improved
glucose tolerance even at 12 h after dosing, whereas the effects of
the other four drugs on improvement in glucose tolerance were
markedly attenuated at 6 h after dosing, resulting in non-signiﬁcant
effects at 12 h after dosing. These results indicate the superiority of
Fig. 3. Effects of SGLT2 inhibitors on blood glucose levels under nonfasting conditions in diabetic mice. (a) Time course of changes in blood glucose levels and the area under the blood glucose concentrationetime curve (AUC) for (b) 8 h
and (c) 24 h. The values are the mean ± SEM for ﬁve animals in each group. *P < 0.05 vs. normal group, #P < 0.05 vs. vehicle group.
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Fig. 4. Effects of SGLT2 inhibitors on plasma insulin levels under nonfasting conditions in diabetic mice. (a) Time course of changes in plasma insulin levels and the area under the plasma insulin concentrationetime curve (AUC) for (b)
8 h and (c) 24 h. The values are the mean ± SEM for ﬁve animals in each group. *P < 0.05 vs. normal group, #P < 0.05 vs. vehicle group.
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correlation of long action with high distribution and long retention
in the kidney, as shown in the pharmacokinetic experiment, and
with a persistent increase in urinary glucose excretion, as
shown in the pharmacodynamics experiment. Based on theseB
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Fig. 7. Durability of SGLT2 inhibitors on glucose tolerance during repetitive oral glucose tolerance tests in diabetic mice. Each SGLT2 inhibitor (3 mg/kg) was administered orally to
diabetic mice fasted for half a day, and glucose solution was orally loaded (a) 0.5, (b) 6, and (c) 12 h after dosing. The values are the mean ± SEM for ﬁve animals in each group.
*P < 0.05 vs. vehicle group.
A. Tahara et al. / Journal of Pharmacological Sciences 130 (2016) 159e169 167pharmacologic experiments conﬁrmed that the daily variability
(standard deviation) of blood glucose and plasma insulin levels was
small with the long-acting SGLT2 inhibitors. A recent study has
suggested that, to improve diabetic conditionsdparticularly com-
plicationsdblood glucose control should be performed with focus
not only on long-term average blood glucose levels using decrease
in HbA1c as a measure, but also on minimizing daily variations in
blood glucose level (22). In addition, the usefulness of new mea-
sures of blood glucose control, including the standard deviation of
blood glucose (SDBG) and mean amplitude of glucose excursion
(MAGE), has been extensively reported (23). Long-acting SGLT2
inhibitors may therefore serve as excellent treatments for diabetes
in terms of not only potency but also quality, by exerting anti-
hyperglycemic effects and improving glucose tolerance through
persistent increases in urinary glucose excretion. In contrast,
intermediate-acting SGLT2 inhibitors may provide better glycemic
control when given twice daily rather than once daily. Clinically, all
SGLT2 inhibitors are prescribed on a once daily basis, likely due in
part to differences in pharmacokinetics betweenmice and humans,
but the efﬁcacy may be enhanced by increasing the duration of
action through modiﬁcations to the formulation.
The OGTT performed to investigate the time to onset of action of
each drug revealed signiﬁcant improvement in glucose tolerance
with ipragliﬂozin and luseogliﬂozin, regardless of time ofadministration with respect to glucose loading, providing evidence
for their superiority of fast onset. These results are consistent with
ﬁndings regarding the shortest Tmax in the pharmacokinetic ex-
periments. Since all SGLT2 inhibitors are at least 100 times more
selective for SGLT2 than for SGLT1, inhibition of SGLT1-mediated
intestinal glucose absorption is likely not involved in the onset or
duration of action. In clinical practice, SGLT2 inhibitors are all
administered once daily, generally before or after breakfast. The
results of this study suggest that fast-acting SGLT2 inhibitors can
exert maximum efﬁcacy regardless of dosing timing, thereby
potentially reducing the aforementioned daily variation in blood
glucose level.
No substantial species-speciﬁc differences in in vitro inhibitory
activity for SGLT2 have been reported among the six SGLT2 in-
hibitors evaluated in the present study (8e13). However, a number
of species-speciﬁc differences in pharmacokinetic properties have
been observed, particularly with respect to elimination half-life of
drug in plasma between humans and rodents including mice.
Therefore, the duration of action in humans may differ from that
noted in mice in our study. The results of the study suggest close
correlation of duration of action with not only plasma drug con-
centration but also drug distribution and retention in the kidney,
warranting further clinical studies on the duration of action of
SGLT2 inhibitors and drug distribution in the kidney.
Fig. 8. Rapid-onset of SGLT2 inhibitors on glucose tolerance during the oral glucose tolerance test in diabetic mice. Each SGLT2 inhibitor (3 mg/kg) was administered orally to
diabetic mice fasted for half a day at 30 min before (left), 5 min before (center), or 10 min after (right) oral glucose loading. (a) Time course of changes in the blood glucose level and
(b) the area under the blood glucose concentrationetime curve (AUC) during the oral glucose tolerance test (OGTT). (c) Plasma insulin level at 30 min during the OGTT. The values
are the mean ± SEM for ﬁve animals in each group. *P < 0.05 vs. vehicle group.
A. Tahara et al. / Journal of Pharmacological Sciences 130 (2016) 159e169168In summary, based on the pharmacokinetic, pharmacody-
namic, and pharmacologic results obtained in this study, the six
SGLT2 inhibitors were classiﬁed with respect to duration of action
as either long-acting or intermediate-acting, and fast-acting drugs
were also identiﬁed. The present study is the ﬁrst to examine and
compare properties of several SGLT2 inhibitors, and we expect our
ﬁndings to be useful for both clinical and nonclinical investigation
of SGLT2 inhibitors for diabetes. Our study involved single
administration, and parameters were limited to blood glucose and
plasma insulin levels and glucose tolerance; therefore, we were
unable to sufﬁciently differentiate SGLT2 inhibitors with respect
to pharmacologic effects. Future studies should conduct detailed
comparison of effects on improvement in type 2 diabetes by
repeated administration based on diversiﬁed pharmacologic pa-
rameters. However, despite these shortcomings, the present re-
sults suggest that while all SGLT2 inhibitors signiﬁcantly increase
urinary glucose excretion and attenuate hyperglycemia, the dif-
ference in the quality of daily blood glucose control associated
with duration and onset of pharmacologic effects of each drug
might result in slightly different degrees of improvement of type 2
diabetes.Conﬂicts of interest
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